| abstract |
The present invention relates to an inhaled anticholinergic agent bronchi for the symptomatic or prophylactic treatment of respiratory diseases, particularly respiratory diseases associated with obstruction or inflammation such as chronic obstructive pulmonary disease (COPD) or asthma. It relates to an inhalation / oral PDE4 inhibitor combination in combination with a dilator (muscarinic receptor antagonist), preferably roflumilast or AWD12-281 and R, R-glycopyrrolate. The present invention further includes presentation of a formulation to be applied topically (inhaled) and application in an inhalation device such as a Novolizer ™. |